Cubicin

Cubicin is a brand name of daptomycin, approved by the FDA in the following formulation(s):

CUBICIN (daptomycin - injectable; iv (infusion))

• 
  Manufacturer: CUBIST
  
  Approval date: September 12, 2003
  
  Strength(s): 500MG/VIAL ^[RLD]

Has a generic version of Cubicin been approved?

No. There is currently no therapeutically equivalent version of Cubicin available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cubicin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Methods for administration of antibiotics
  Patent 6,468,967
  Issued: October 22, 2002
  Inventor(s): Frederick B.; Oleson, Jr. & Francis P.; Tally
  Assignee(s): Cubist Pharmaceuticals, Incorporated
  The invention provides methods for administering a therapeutically effective amount of daptomycin while minimizing skeletal muscle toxicity. The methods provide daptomycin administration at a dosing interval of 24 hours or greater. This long dosing interval minimizes skeletal muscle toxicity and allows for higher peak concentrations of daptomycin, which is related to daptomycin's efficacy. The invention also provides methods of administering lipopeptide antibiotics other than daptomycin while minimizing skeletal muscle toxicity by administering a therapeutically effective amount of the lipopeptide antibiotic at a dosage interval that does not result in muscle toxicity. The invention also provides methods of administering quinupristin/dalfopristin while minimizing skeletal muscle toxicity by administering a therapeutically effective amount of quinupristin/dalfopristin at a dosage interval that does not result in muscle toxicity.
  
  Patent expiration dates:
  
  
  • September 24, 2019
    
    ✓ 
    Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
  
  



• 
  Methods for administration of antibiotics
  Patent 6,852,689
  Issued: February 8, 2005
  Inventor(s): Oleson, Jr.; Frederick B. & Tally; Francis P.
  Assignee(s): Cubist Pharmaceuticals, Inc.
  The invention provides methods for administering a therapeutically effective amount of daptomycin while minimizing skeletal muscle toxicity. The methods provide daptomycin administration at a dosing interval of 24 hours or greater. This long dosing interval minimizes skeletal muscle toxicity and allows for higher peak concentrations of daptomycin, which is related to daptomycin's efficacy. The invention also provides methods of administering lipopeptide antibiotics other than daptomycin while minimizing skeletal muscle toxicity by administering a therapeutically effective amount of the lipopeptide antibiotic at a dosage interval that does not result in muscle toxicity. The invention also provides methods of administering quinupristin/dalfopristin while minimizing skeletal muscle toxicity by administering a therapeutically effective amount of quinupristin/dalfopristin at a dosage interval that dos not result in muscle toxicity.
  
  Patent expiration dates:
  
  
  • September 24, 2019
    
    ✓ 
    Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
  
  



• 
  Daptomycin for the treatment of biofilm and catheter salvage
  Patent 8,003,673
  Issued: August 23, 2011
  Inventor(s): Alder; Jeffrey & Silverman; Jared & Mortin; Lawrence & Van Praagh; Andrew
  Assignee(s): Cubist Pharmaceuticals, Inc.
  Daptomycin can be used for biofilm treatment (particularly central venous catheter salvage for S. epidermidis infected catheters). Catheter salvage with daptomycin shows rapid cidality, activity against stationary phase bacteria, and penetration and activity in biofilms. The present inventions provide formulations, methods, and articles of manufacture useful for biofilm treatment or catheter salvage involving daptomycin. Particular formulations include daptomycin in lactated Ringer's solution having a rapid kill curve against the bacteria of the biofilm.
  
  Patent expiration dates:
  
  
  • September 4, 2028
    
    ✓ 
    Patent use: TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS
  
  



• 
  High purity lipopeptides
  Patent 8,058,238
  Issued: November 15, 2011
  Inventor(s): Kelleher; Thomas & Lai; Jan-Ji & DeCourcey; Joseph P. & Lynch; Paul & Zenoni; Maurizio & Tagliani; Auro
  Assignee(s): Cubist Pharmaceuticals, Inc.
  The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of Streptomyces roseosporus. The invention also discloses high pressure liquid chromatography methods for analysis of daptomycin purity. The invention also discloses lipopeptide micelles and methods of making the micelles. The invention also discloses methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin. The invention also discloses using lipopeptide micelles therapeutically.
  
  Patent expiration dates:
  
  
  • November 28, 2020
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Anhydro-and isomer-a-21978c cyclic peptides
  Patent RE39071
  Issued: April 18, 2006
  Inventor(s): Baker; Patrick J. & Debono; Manuel & Farid; Khadiga Z. & Molloy; R. Michael
  Assignee(s): Eli Lilly and Company
  Two new groups of A-21978C cyclic peptides, anhydro- and isomer-A21978C peptide derivatives, have antibacterial activity and are useful as intermediates. The two groups are prepared via transpeptidation of the parent cyclic peptides. Pharmaceutical formulations containing the new peptides as active ingredients and methods of treating infections caused by susceptible Gram-positive bacteria with the formulations are also provided. The invention also provides an antibacterial composition containing the new drug substance LY 146032 in substantially pure form.
  
  Patent expiration dates:
  
  
  • June 15, 2016
    
    ✓ 
    Patent use: METHOD FOR TREATING BACTERIAL INFECTION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• Cubicin Consumer Information (Drugs.com)
• Cubicin Consumer Information (Wolters Kluwer)
• Cubicin Consumer Information (Cerner Multum)
• Cubicin Advanced Consumer Information (Micromedex)
• Cubicin AHFS DI Monographs (ASHP)
• Daptomycin Consumer Information (Wolters Kluwer)
• Daptomycin Consumer Information (Cerner Multum)
• Daptomycin Intravenous Advanced Consumer Information (Micromedex)
• Daptomycin AHFS DI Monographs (ASHP)